Kestra Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Kestra Advisory Services’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$52.2K	Sell	16,999 -13,152	-44%	-$50.8K	﹤0.01%	3058
2025 Q4	$123K	Sell	30,151 -2,666	-8%	-$13.2K	﹤0.01%	3260
2025 Q3	$160K	Sell	32,817 -348	-1%	-$1.83K	﹤0.01%	2775
2025 Q2	$168K	Sell	33,165 -9,990	-23%	-$49.1K	﹤0.01%	2680
2025 Q1	$228K	Buy	43,155 +15,153	+54%	+$110K	﹤0.01%	2385
2024 Q4	$189K	Buy	+28,002	New	+$188K	﹤0.01%	2500

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kestra Advisory Services's RXRX Position: Q1 2026 in Review

Kestra Advisory Services reduced its Recursion Pharmaceuticals (RXRX) stake by 44% in Q1 2026, selling an estimated $50.8K and leaving 16,999 shares worth $52.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3058.

Kestra Advisory Services first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $228K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Kestra Advisory Services held 16,999 shares of Recursion Pharmaceuticals worth $52.2K as of Q1 2026.
Kestra Advisory Services sold 13,152 Recursion Pharmaceuticals shares in Q1 2026, an estimated $50.8K.
Recursion Pharmaceuticals made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #3058 holding.
Kestra Advisory Services first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Kestra Advisory Services's Recursion Pharmaceuticals position peaked at $228K in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.